ArticleBMC medical imaging2026
A nomogram for malignancy prediction of pancreatic cystic lesions based on trans-abdominal ultrasound features.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPancreatic cystic lesions (PCLs) have variable malignant potential, and distinguishing benign from malignant/premalignant cysts is challenging for optimal management. Trans-abdominal ultrasound (TAUS), a widely available, non-invasive, low-cost first-line pancreatic imaging tool, is underexplored for predicting PCL malignant potential. This study aimed to develop a TAUS feature-based nomogram for this purpose.
methodsThis retrospective study included 161 patients with pathology-confirmed PCLs from December 2012 to July 2021, divided into benign (59 cases) and non-benign (premalignant/malignant, 102 cases) groups. Relevant clinical characteristics and TAUS features were collected. Least absolute shrinkage and selection operator (LASSO) logistic regression analysis was used to optimize feature selection. Multivariate logistic regression analysis was applied to construct the nomogram. The performance of the nomogram was assessed via receiver operating characteristic curves, calibration curves and decision curve analysis (DCA).
resultsAmong the 26 features collected, 11 features were chosen via LASSO analysis. Multivariate analysis identified echogenicity, the configuration of cysts, solid content and septation/wall thickening as independent predictors. The prediction nomogram model developed with these four variables showed moderate discriminative performance in differentiating non-benign from benign PCLs, with an area under the curve (AUC) of 0.781. Regarding internal verification, tenfold cross-validation yielded a C-index of 0.749. The Hosmer-Lemeshow test yielded a P = 0.945, suggesting that the model had a good fit. Additionally, DCA demonstrated good net clinical benefit.
conclusionsThis study explored the value of TAUS features for predicting the malignant potential of PCLs. The incorporation of TAUS features into a nomogram may offer a potential non-invasive tool to help clinicians in risk stratification during the initial evaluation and follow-up assessment of PCLs patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.